Tango Therapeutics, Inc. (TNGX) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Tango Therapeutics, Inc. (TNGX) Bundle
As an investor or analyst, the Tango Therapeutics, Inc. (TNGX) DCF Calculator is your go-to resource for accurate valuation. Featuring real data from Tango Therapeutics, you can adjust forecasts and instantly observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.6 | 7.7 | 37.0 | 24.9 | 36.5 | 40.6 | 45.2 | 50.3 | 56.0 | 62.3 |
| Revenue Growth, % | 0 | -68.94 | 383.83 | -32.89 | 46.93 | 11.28 | 11.28 | 11.28 | 11.28 | 11.28 |
| EBITDA | -14.5 | -51.5 | -57.3 | -109.5 | -111.8 | -37.3 | -41.5 | -46.2 | -51.4 | -57.2 |
| EBITDA, % | -58.9 | -672.44 | -154.67 | -440.32 | -305.96 | -91.78 | -91.78 | -91.78 | -91.78 | -91.78 |
| Depreciation | .6 | 1.6 | 2.0 | 4.0 | 2.4 | 4.2 | 4.7 | 5.2 | 5.8 | 6.5 |
| Depreciation, % | 2.61 | 21.23 | 5.31 | 16.2 | 6.61 | 10.39 | 10.39 | 10.39 | 10.39 | 10.39 |
| EBIT | -15.2 | -53.1 | -59.3 | -113.5 | -114.2 | -37.5 | -41.7 | -46.5 | -51.7 | -57.5 |
| EBIT, % | -61.51 | -693.67 | -159.98 | -456.52 | -312.57 | -92.3 | -92.3 | -92.3 | -92.3 | -92.3 |
| Total Cash | 40.4 | 190.3 | 485.3 | 366.1 | 336.9 | 40.6 | 45.2 | 50.3 | 56.0 | 62.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | 2.0 | 2.0 | 2.0 | .0 | 3.2 | 3.6 | 4.0 | 4.4 | 4.9 |
| Account Receivables, % | 0 | 26.12 | 5.4 | 8.05 | 0 | 7.91 | 7.91 | 7.91 | 7.91 | 7.91 |
| Inventories | .0 | .0 | .6 | .6 | .0 | .3 | .3 | .4 | .4 | .5 |
| Inventories, % | 0 | 0 | 1.53 | 2.28 | 0 | 0.76229 | 0.76229 | 0.76229 | 0.76229 | 0.76229 |
| Accounts Payable | .7 | 1.8 | 3.2 | 4.5 | 2.8 | 5.0 | 5.5 | 6.1 | 6.8 | 7.6 |
| Accounts Payable, % | 2.72 | 24.05 | 8.71 | 17.91 | 7.62 | 12.2 | 12.2 | 12.2 | 12.2 | 12.2 |
| Capital Expenditure | -1.8 | -1.1 | -1.8 | -7.7 | -1.5 | -5.0 | -5.6 | -6.2 | -6.9 | -7.7 |
| Capital Expenditure, % | -7.37 | -14.45 | -4.96 | -30.94 | -4.18 | -12.38 | -12.38 | -12.38 | -12.38 | -12.38 |
| Tax Rate, % | -0.13188 | -0.13188 | -0.13188 | -0.13188 | -0.13188 | -0.13188 | -0.13188 | -0.13188 | -0.13188 | -0.13188 |
| EBITAT | -15.2 | -53.0 | -59.6 | -113.5 | -114.3 | -37.5 | -41.7 | -46.4 | -51.7 | -57.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -15.7 | -53.3 | -58.6 | -116.0 | -112.5 | -39.7 | -42.5 | -47.3 | -52.6 | -58.5 |
| WACC, % | 8.12 | 8.11 | 8.12 | 8.12 | 8.12 | 8.12 | 8.12 | 8.12 | 8.12 | 8.12 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -188.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -60 | |||||||||
| Terminal Value | -976 | |||||||||
| Present Terminal Value | -661 | |||||||||
| Enterprise Value | -849 | |||||||||
| Net Debt | -27 | |||||||||
| Equity Value | -822 | |||||||||
| Diluted Shares Outstanding, MM | 95 | |||||||||
| Equity Value Per Share | -8.69 |
What You Will Get
- Comprehensive TNGX Financials: Access to both historical data and future projections for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically in real-time.
- Scenario Analysis: Explore various scenarios to assess Tango Therapeutics' potential performance.
- User-Friendly Interface: Designed for industry professionals while remaining easy to navigate for newcomers.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Tango Therapeutics, Inc. (TNGX).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to reflect market conditions.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Tango Therapeutics, Inc. (TNGX).
- Interactive Dashboard and Charts: Visual representations of key valuation metrics for straightforward analysis.
How It Works
- Download: Get the comprehensive Excel file featuring Tango Therapeutics' (TNGX) financial data.
- Customize: Tailor your forecasts, including revenue growth, EBITDA %, and WACC.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare results.
- Make Decisions: Leverage the valuation outcomes to inform your investment approach.
Why Choose Tango Therapeutics Calculator?
- Comprehensive Tool: Incorporates DCF, WACC, and financial ratio analyses tailored for Tango Therapeutics (TNGX).
- Customizable Inputs: Modify yellow-highlighted cells to explore different financial scenarios for TNGX.
- Detailed Insights: Automatically computes Tango Therapeutics’ intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and healthcare consultants focused on TNGX.
Who Should Use Tango Therapeutics, Inc. (TNGX)?
- Investors: Make informed decisions with insights into innovative therapeutic developments.
- Healthcare Analysts: Streamline your research with comprehensive data on drug pipelines and market potential.
- Consultants: Easily modify presentations for clients focused on biotechnology and pharmaceuticals.
- Biotech Enthusiasts: Enhance your knowledge of cutting-edge therapies and their implications in healthcare.
- Educators and Students: Utilize it as a valuable resource for courses in biotechnology and pharmaceutical sciences.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Tango Therapeutics.
- Real-World Data: Tango Therapeutics’ historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics specific to Tango Therapeutics.
- Dashboard with Visual Outputs: Visual representations including charts and tables for clear, actionable results.